ストックスクリーナーアプリを入手
68.76
1.39%
0.94
アフターアワーズ：
68.76
前日終値:
$67.82
開ける：
$68.03
24時間の取引高:
1.89M
Relative Volume:
0.74
時価総額：
$15.29B
収益：
$4.03B
当期純損益:
$556.70M
株価収益率:
29.01
EPS:
2.37
ネットキャッシュフロー:
$970.10M
1週間 パフォーマンス:
-0.32%
1か月 パフォーマンス:
+7.45%
6か月 パフォーマンス:
+6.90%
1年 パフォーマンス:
-15.02%
1日の値動き範囲:
$67.74
$68.79
1週間の範囲:
$67.05
$69.03
52週間の値動き範囲:
$51.90
$84.39
Hologic Inc Stock (HOLX) Company Profile
HOLX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HOLX
Hologic Inc
|
68.76 | 14.96B | 4.03B | 556.70M | 970.10M | 2.37 |
|
ISRG
Intuitive Surgical Inc
|
480.45 | 172.53B | 9.15B | 2.63B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
199.20 | 55.89B | 21.39B | 1.61B | 2.55B | 5.56 |
|
ALC
Alcon Inc
|
81.04 | 43.59B | 9.93B | 1.12B | 1.43B | 2.26 |
|
RMD
Resmed Inc
|
289.06 | 41.89B | 5.15B | 1.40B | 1.65B | 9.51 |
|
WST
West Pharmaceutical Services Inc
|
246.38 | 17.48B | 2.96B | 487.70M | 344.00M | 6.68 |
Hologic Inc Stock (HOLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-06 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-07-09 | アップグレード | Citigroup | Neutral → Buy |
| 2025-05-27 | 繰り返されました | Needham | Hold |
| 2025-03-03 | ダウングレード | Argus | Buy → Hold |
| 2025-02-06 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-02-03 | ダウングレード | Needham | Buy → Hold |
| 2024-12-13 | 開始されました | Wolfe Research | Peer Perform |
| 2024-12-10 | 開始されました | Jefferies | Hold |
| 2024-12-10 | 繰り返されました | Needham | Buy |
| 2024-10-01 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-06-27 | 開始されました | Stephens | Overweight |
| 2024-04-03 | アップグレード | Citigroup | Neutral → Buy |
| 2023-07-14 | アップグレード | Needham | Hold → Buy |
| 2022-12-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2022-10-13 | 開始されました | Mizuho | Buy |
| 2022-07-20 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-07-20 | 開始されました | UBS | Neutral |
| 2022-07-18 | ダウングレード | BTIG Research | Buy → Neutral |
| 2022-04-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2021-12-15 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-10-14 | 開始されました | Redburn | Neutral |
| 2021-07-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2020-11-20 | ダウングレード | Needham | Buy → Hold |
| 2020-11-05 | 繰り返されました | Needham | Buy |
| 2020-06-30 | アップグレード | Cowen | Market Perform → Outperform |
| 2020-06-03 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2020-04-30 | 繰り返されました | Needham | Buy |
| 2020-04-30 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-04-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-03-27 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2020-01-13 | 繰り返されました | Needham | Buy |
| 2020-01-08 | 開始されました | Wells Fargo | Equal Weight |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2020-01-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-09-26 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-08-01 | 繰り返されました | Needham | Buy |
| 2019-05-02 | 繰り返されました | Needham | Buy |
| 2019-01-31 | 繰り返されました | Needham | Buy |
| 2019-01-02 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2018-10-09 | 開始されました | UBS | Neutral |
| 2018-09-13 | ダウングレード | BofA/Merrill | Buy → Neutral |
すべてを表示
Hologic Inc (HOLX) 最新ニュース
Here's Why Hologic (HOLX) is a Strong Value Stock - Yahoo Finance
What's Behind Hologic's Positive Long-Term Outlook for Cytology Unit? - Yahoo Finance
Stock Analysis | Hologic OutlookMixed Signals Amid Strong Fundamentals and Divergent Analyst Views - AInvest
Hologic Inc. Approaches Support With Recovery in Sight2025 Key Highlights & Reliable Trade Execution Plans - classian.co.kr
Argus Upgrades Hologic to Buy From Hold, Price Target is $80 - MarketScreener
Will Hologic Inc. benefit from current market trendsPortfolio Risk Summary & AI Powered Market Entry Strategies - sundaytimes.kr
What to Expect From Hologic's Q3 2025 Earnings Report - MSN
Does Hologic Inc. have high return on assets2025 Short Interest & Weekly High Potential Stock Alerts - classian.co.kr
Saliva-based Screening Market CAGR 7.70% Trends with Thermo - openPR.com
Hologic Reports Strong Q3 2025 Earnings, Exceeds Guidance - MSN
Stephens Adjusts Price Target on Hologic to $78 From $70 - MarketScreener
Is Trending Stock Hologic, Inc. (HOLX) a Buy Now? - Yahoo Finance
Hologic Eyes Organic Growth Rebound in 2026 on Breast Health Strength - MSN
Hologic Management to Meet Virtually with BTIG on August 21 - AInvest
Hologic's Growth Prospects and Undervalued Stock Support Buy Rating - AInvest
Hologic Stock Performance: Underperforms Market Despite Quarterly GainsNews and Statistics - IndexBox
Hologic Stock Target Price: A Closer Look - AInvest
What Are Wall Street Analysts' Target Price for Hologic Stock? - MSN
What Are Wall Street Analysts' Target Price For Hologic Stock? - Barchart.com
Body Fat Measurement Market to Witness Growth and Comprehensive - openPR.com
Hologic’s Q2 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
HOLX Q2 Deep Dive: Breast Health Turnaround and New Product Launches Drive Momentum - FinancialContent
STD Diagnostic Market Forecast and Company Analysis Report - GlobeNewswire
STD Diagnostic Market Forecast and Company Analysis Report 2025-2033 Featuring Siemens, Abbott, MedMira, QIAGEN, Danaher, F. Hoffmann-La Roche, Diasorin, BioMeriuex, Hologic, Bio-Rad Laboratories - Yahoo Finance
Hologic's Diagnostics Arm Set for Long-Term Upside: What's Behind It? - MSN
Hologic's Diagnostics Arm Set For Long-Term Upside: What's Behind It? - Barchart.com
There May Be Some Bright Spots In Hologic's (NASDAQ:HOLX) Earnings - Yahoo Finance
RadNet hires Hologic, Bausch + Lomb alum Jane Mazur - Medical Marketing and Media
Hologic’s Growth Story Looks Set For A Comeback - Finimize
RBC Capital Reiterates Buy Rating for Hologic with $87 Price Target - AInvest
RBC Capital Upgrades Hologic (HOLX) to Outperform with Raised Pr - GuruFocus
Forecasting the Future: Next-Generation Biopsy-Based Cancer - openPR.com
Should You Buy, Sell or Hold Hologic Stock Post Q3 Earnings? - The Globe and Mail
Should You Buy, Sell Or Hold Hologic Stock Post Q3 Earnings? - Barchart.com
Hpv And Pap Testing Market Generated Opportunities, Future - openPR.com
RBC Capital Upgrades Hologic to Outperform From Sector Perform, Adjusts PT to $87 From $72 - MarketScreener
RBC Capital upgrades Hologic stock to Outperform on expected growth By Investing.com - Investing.com Canada
RBC Capital upgrades Hologic stock to Outperform on expected growth - Investing.com
Molecular Diagnostics Market Expands with Infectious Disease - openPR.com
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know - MSN
Analysts Have Made A Financial Statement On Hologic, Inc.'s (NASDAQ:HOLX) Third-Quarter Report - simplywall.st
Why Hologic (HOLX) is a Top Value Stock for the Long-Term - Yahoo Finance
Interpreting Hologic (HOLX) International Revenue Trends - Yahoo Finance
Hologic Inc (HOLX) 財務データ
収益
当期純利益
現金流量
EPS
Hologic Inc (HOLX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mitchell Essex D | Chief Operating Officer |
Dec 04 '24 |
Option Exercise |
62.60 |
22,902 |
1,433,659 |
52,813 |
| Mitchell Essex D | Chief Operating Officer |
Dec 04 '24 |
Sale |
76.34 |
24,856 |
1,897,482 |
27,957 |
0.70%
0.80%
大文字化:
|
ボリューム (24 時間):